Keywords: Sanofi-Aventis, Second-quarter 2010 fiancial results, Genzyme M&A rumors, Lovenox, Law suti, FDA

Sanofi-Aventis 2nd-qtr 2010 earnings up 8%, but firm still mute on Genzyme acquisition; sues over Lovenox

Article | 29 July 2010

Sanofi Aventis posted a strong set of second-quarter 2010 results this morning, but the company’s chief executive Chris Viehbacher, unveiling the financials in Paris, remained tight-lipped about the French drug major’s interest in acquiring troubled US biotechnology firm Genzyme, as has been rumoured for around a week (The Pharma Letter July 26 and 27).

M Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in